Abstract
Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more aggressive potential of the disease. Multigene tests provide detailed insights into tumour biology by simultaneously testing several prognostically relevant genes. With OncotypeDX®, a panel of 21 genes is tested by means of quantitative real-time polymerase chain reaction. The purpose of this pilot study was to analyse whether a combination of Ki67 and uPA/PAI-1 supplies indications of the result of the multigene test. The results of Ki67, uPA/PAI-1 and OncotypeDX® were analysed in 25 breast carcinomas (luminal type, pT1/2, max pN1a, G2). A statistical and descriptive analysis was performed. With a proliferation index Ki67 of < 14%, the recurrence score (RS) from the multigene test was on average in the low risk range, with an intermediate RS usually resulting if Ki67 was > 14%. Not elevated values of uPA and PAI-1 showed a lower rate of proliferation (average 8.5%) t...Continue Reading
References
Jan 1, 1993·Breast Cancer Research and Treatment·F JänickeH Graeff
Aug 19, 2000·Cellular and Molecular Life Sciences : CMLS·P A AndreasenH H Petersen
Sep 9, 2000·Current Opinion in Cell Biology·K T PreissnerA E May
Jan 17, 2002·Journal of the National Cancer Institute·Maxime P LookJohn A Foekens
Jul 25, 2003·Current Pharmaceutical Design·Steven Rosenberg
Apr 20, 2004·Journal of Cellular Biochemistry·Yabing ChenDavid J Schneider
May 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soonmyung PaikNorman Wolmark
Apr 28, 2007·Clinical Chemistry·Maureen CroninDrew Watson
May 23, 2008·Immunology Letters·Bernd R Binder, Judit Mihaly
Aug 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lori J GoldsteinJoseph A Sparano
Feb 10, 2009·Current Cancer Drug Targets·Salvatore UlisseMassimino D'Armiento
Dec 17, 2009·The Lancet Oncology·Kathy S AlbainUNKNOWN Breast Cancer Intergroup of North America
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Jan 22, 2013·The Breast : Official Journal of the European Society of Mastology·D S LangT Goldmann
Mar 16, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N HarbeckUNKNOWN Chemo-N 0 Study Group
Aug 27, 2013·Breast Cancer Research and Treatment·Josh J Carlson, Joshua A Roth
Dec 3, 2014·Annales de pathologie·Jean-Pierre BellocqValérie Mazeau-Woynar
Dec 17, 2014·OncoTargets and Therapy·Isabell WitzelVolkmar Müller
May 23, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Marko ButaDragica Nikolić-Vukosavljević
Sep 26, 2015·Cancer Biomarkers : Section a of Disease Markers·Zaki Abu RabiDragica Nikolić-Vukosavljević
Feb 3, 2016·Radiology and Oncology·Maja LampeljIztok Takac
Feb 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay N HarrisUNKNOWN American Society of Clinical Oncology
Sep 29, 2017·BMC Cancer·Elise DelucheNicole Tubiana-Mathieu
May 31, 2018·Archives of Pathology & Laboratory Medicine·Antonio C WolffMitchell Dowsett
Citations
Jul 31, 2019·Journal of Clinical Laboratory Analysis·Seth B SereffJames L Wittliff
Sep 11, 2019·Cancers·Geetanjali SainiRitu Aneja
Dec 2, 2020·Cancers·Yen-Yun WangShyng-Shiou F Yuan
Jan 6, 2021·Molecular and Cellular Biochemistry·Ma Eugenia Garay-SevillaArmando Rojas
Apr 21, 2021·Expert Review of Molecular Diagnostics·Rajesh AhirwarSaroj Kumar
Dec 4, 2020··Ammar Rasoul Mohammed RudhaZahraa Mohammed AL-Nafakh